{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:06:08Z","timestamp":1788476768865,"version":"build-2803163510"},"reference-count":145,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG KO2155\/6-1 and KO2155\/7-1"],"award-info":[{"award-number":["DFG KO2155\/6-1 and KO2155\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG CH1509\/1-1"],"award-info":[{"award-number":["DFG CH1509\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interreg V Program","award":["OncoCare"],"award-info":[{"award-number":["OncoCare"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hematopoiesis is a highly regulated and complex process involving hematopoietic stem cells (HSCs), cell surface adhesion molecules, and cytokines as well as cells of the hematopoietic niche in the bone marrow (BM). Myeloproliferative neoplasms (MPNs) are characterized by clonal expansion of HSCs involving one or more blood cell lineages. Philadelphia-negative MPNs (Ph-neg MPNs) comprise polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In nearly all patients with Ph-neg MPN, mutations in the genes encoding janus kinase 2 (JAK2), calreticulin (CALR), or the thrombopoietin receptor (MPL) can be detected and, together with additional mutations in epigenetic modifier genes, these genetic aberrations contribute to the clonal expansion of the cells. In addition to these intracellular changes in the malignant clone, inflammatory processes involving both the clonal and the non-clonal cells contribute to the signs and symptoms of the patients, as well as to progression of the disease to myelofibrosis (MF) or acute leukemia, and to thrombotic complications. This contribution has been corroborated in preclinical studies including mouse models and patient-derived iPS cells, and in clinical trials, using anti-inflammatory drugs such as JAK inhibitors and steroids, or immunomodulatory drugs such as IMiDs and interferon-alpha (IFNa), all of which change the (im)balance of circulating inflammatory factors (e.g., TNFa, IL-1b, and TGF\u03b2) in MPN. Currently, allogeneic hematopoietic (stem) cell transplantation (allo-HCT) remains the only curative treatment for Ph-neg MPN and is the treatment of choice in intermediate-2 and high-risk MF. HCT can reverse inflammatory changes induced by MPN as well as fibrosis in a large proportion of patients, but it also induces itself profound changes in inflammatory cells and cytokines in the patient, which may help to eradicate the disease but also in part cause significant morbidity (e.g., by graft-versus-host disease). In this review, we focus on the contribution of aberrant inflammation to disease pathogenesis in Ph-neg MPN as well as the current understanding of its alterations after allogeneic HCT.<\/jats:p>","DOI":"10.3390\/cancers12082250","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T09:14:49Z","timestamp":1597223689000},"page":"2250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4485-3120","authenticated-orcid":false,"given":"Nicolas","family":"Chatain","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev-pathol-012615-044454","article-title":"Pathogenesis of Myeloproliferative Disorders","volume":"11","author":"Nangalia","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs. JAK2 vs. MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Nivarthi","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1248011","DOI":"10.1080\/21623996.2016.1248011","article-title":"Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics","volume":"5","author":"Langabeer","year":"2016","journal-title":"JAK-STAT"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kirschner, M.M.J., Schemionek, M., Schubert, C., Chatain, N., Sontag, S., Isfort, S., Ortiz-Br\u00fcchle, N., Schmitt, K., Kr\u00fcger, L., and Zerres, K. (2015). Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123476"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"606819","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Koschmieder, S., and Chatain, N. (2020). Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev., 100711. in press.","DOI":"10.1016\/j.blre.2020.100711"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing","volume":"73","author":"Buck","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri1684","article-title":"The yin and yang of type I interferon activity in bacterial infection","volume":"5","author":"Decker","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: Input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"Plenge","year":"2012","journal-title":"Immunity"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-016-0275-0","article-title":"Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion","volume":"9","author":"Han","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and myeloproliferative neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms","volume":"14","author":"Blackmon","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM200103083441016","article-title":"Stem-cell transplantation for myelofibrosis","volume":"344","author":"Deeg","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_24","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Ce","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","article-title":"Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis","volume":"98","author":"Anderson","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_30","unstructured":"Mein, P., and M\u00fcller, C. (2020, June 28). ZKRD Zentrales Knochenmarkspender-Register Deutschland German Standards for Unrelated Blood Stem Cell Donations. Available online: https\/\/www.ebmt.org\/regulations-guidelines."},{"key":"ref_31","unstructured":"Eva, L., Grie\u00dfhammer, M., and Petrides, P.E. (2020, June 28). Myeloproliferative Neoplasien (MPN) (Fr\u00fcher: Chronische Myeloproliferative Erkrankungen (CMPE)). Available online: https\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/myeloproliferative-neoplasien-mpn-frueher-chronische-myeloproliferative-erkrankungen-cmpe\/@@guideline\/html\/index.html."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Holler","year":"2009","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I Treat","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00259-014-2983-4","article-title":"Assessment of bone marrow inflammation in patients with myelofibrosis: An 18F-fluorodeoxyglucose PET\/CT study","volume":"42","author":"Derlin","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/cam4.835","article-title":"Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients","volume":"5","author":"Morel","year":"2016","journal-title":"Cancer Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcmd.2014.12.005","article-title":"Activation of non-canonical TGF-\u03b21 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis","volume":"54","author":"Ciaffoni","year":"2015","journal-title":"Blood Cells. Mol. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"453020","DOI":"10.1155\/2015\/453020","article-title":"Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms","volume":"2015","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-018-0131-z","article-title":"Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion","volume":"32","author":"Heaton","year":"2018","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10428194.2010.531413","article-title":"Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera","volume":"52","author":"Allegra","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2014-04-570572","article-title":"JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2","volume":"124","author":"Kagoya","year":"2014","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","article-title":"Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2018-02-834820","article-title":"The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis","volume":"131","author":"Kramann","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb3530","article-title":"Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis","volume":"19","author":"Decker","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","article-title":"JAK2V617F but not CALR mutations confer increased molecular responses to interferon-\u03b1 via JAK1\/STAT1 activation","volume":"33","author":"Czech","year":"2019","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-019-0722-9","article-title":"Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha","volume":"12","author":"Schubert","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wong, W.J., Baltay, M., Getz, A., Fuhrman, K., Aster, J.C., Hasserjian, R.P., and Pozdnyakova, O. (2019). Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216810"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2007.10.004","article-title":"Dendritic cells and cytokines in human inflammatory and autoimmune diseases","volume":"19","author":"Blanco","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2018-05-850321","article-title":"Murine myeloproliferative disorder as a consequence of impaired collaboration between dendritic cells and CD4 T cells","volume":"133","author":"Barber","year":"2019","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Bj\u00f8rn, M.E., and Hasselbalch, H.C. (2015). The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediat. Inflamm., 2015.","DOI":"10.1155\/2015\/648090"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-018-0797-0","article-title":"Reactive oxygen species in haematopoiesis: Leukaemic cells take a walk on the wild side","volume":"37","author":"Ijurko","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature10363","article-title":"Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase","volume":"477","author":"Frezza","year":"2011","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1158\/1078-0432.CCR-18-3777","article-title":"Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis","volume":"25","author":"Merlinsky","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2(V617F) myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41375-019-0629-z","article-title":"Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms","volume":"34","author":"Baumeister","year":"2020","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/bloodadvances.2019000967","article-title":"N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm","volume":"4","author":"Craver","year":"2020","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10238-009-0058-9","article-title":"Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis","volume":"10","author":"Bacher","year":"2010","journal-title":"Clin. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/leu.2016.324","article-title":"Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients","volume":"31","author":"Neumann","year":"2017","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.scr.2015.01.004","article-title":"Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients","volume":"14","author":"Kim","year":"2015","journal-title":"Stem Cell Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: Pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1365-2141.2000.01826.x","article-title":"Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: Evidence for a \u201cgraft vs. myelofibrosis\u201d effect","volume":"108","author":"Byrne","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_73","first-page":"633","article-title":"Standardization of bone marrow features\u2014Does it work in hematopathology for histological discrimination of different disease patterns?","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","article-title":"Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis","volume":"20","author":"Zabelina","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.bmt.1702568","article-title":"Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: Demonstration of a graft-versus-myelofibrosis effect","volume":"26","author":"Cervantes","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjh.12013","article-title":"Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting","volume":"159","author":"Klyuchnikov","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Cornez","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.stem.2019.06.007","article-title":"Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging","volume":"25","author":"Ho","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40610-017-0055-9","article-title":"The osteoblastic niche in hematopoiesis and hematological myeloid malignancies","volume":"3","author":"Kousteni","year":"2017","journal-title":"Curr. Mol. Biol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1148\/radiology.175.1.2315484","article-title":"Red and yellow marrow in the femur: Age-related changes in appearance at MR imaging","volume":"175","author":"Moore","year":"1990","journal-title":"Radiology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.169.3942.291","article-title":"Bone marrow histogenesis: A comparison of fatty and red marrow","volume":"169","author":"Tavassoli","year":"1970","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2013-05-501460","article-title":"Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression","volume":"122","author":"Laperrousaz","year":"2013","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11914-013-0180-1","article-title":"Osteoporosis after stem cell transplantation","volume":"11","author":"McClune","year":"2013","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1210\/jc.2006-2870","article-title":"REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation","volume":"92","author":"Colao","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.bmt.1704535","article-title":"Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation","volume":"34","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2009-11-253559","article-title":"Bone marrow graft-versus-host disease: Early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation","volume":"115","author":"Shono","year":"2010","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2010-07-297598","article-title":"Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms","volume":"117","author":"Teofili","year":"2011","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jbior.2018.06.003","article-title":"The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells","volume":"69","author":"Kaushansky","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1097\/HS9.0000000000000364","article-title":"Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis","volume":"4","author":"Guy","year":"2020","journal-title":"HemaSphere"},{"key":"ref_99","first-page":"365","article-title":"Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation","volume":"22","author":"Thiele","year":"2007","journal-title":"Histol. Histopathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2012.04.011","article-title":"Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation","volume":"18","author":"Wong","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Boluda, J.C., Pereira, A., Kr\u00f6ger, N., Beelen, D., Robin, M., Bornh\u00e4user, M., Angelucci, E., Vitek, A., Blau, I.W., and Niittyvuopio, R. (2020). Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Leukemia, 1\u201310.","DOI":"10.1038\/s41375-020-0815-z"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Malcovati","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3324\/haematol.2010.031229","article-title":"Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis","volume":"96","author":"Zabelina","year":"2011","journal-title":"Haematologica"},{"key":"ref_105","first-page":"879","article-title":"Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/leu.2014.97","article-title":"Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms","volume":"28","author":"Avanzini","year":"2014","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1704172","article-title":"FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia","volume":"32","author":"Tanner","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bbmt.2015.12.006","article-title":"Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis","volume":"22","author":"Hussein","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease","volume":"44","author":"Liongue","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_111","first-page":"52","article-title":"Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia","volume":"87","author":"Mengarelli","year":"2002","journal-title":"Haematologica"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/10428199309147359","article-title":"High dose hydroxyurea in collection of Philadelphia chromosome-negative stem cells in chronic myeloid leukaemia","volume":"10","author":"Kuss","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Malato, A., Rossi, E., Tiribelli, M., Mendicino, F., and Pugliese, N. (2020). Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications. Clin. Lymphoma. Myeloma Leuk., 1\u20138.","DOI":"10.1016\/j.clml.2020.04.015"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.leu.2402043","article-title":"Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation","volume":"15","author":"Li","year":"2001","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: Allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/leu.2014.86","article-title":"JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET\/PV myelofibrosis","volume":"28","author":"Alchalby","year":"2014","journal-title":"Leukemia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms","volume":"75","author":"Rudolph","year":"2015","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/TXD.0000000000000607","article-title":"Evaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors","volume":"2","author":"Shiratori","year":"2016","journal-title":"Transplant. Direct"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT\/ELN international working group","volume":"29","author":"Deeg","year":"2015","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic Inhibition of JAK1\/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: A multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.bbmt.2019.09.022","article-title":"Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome\u2013Positive Acute Lymphoblast Leukemia: A Systematic Review","volume":"26","author":"Warraich","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.retram.2018.07.001","article-title":"Clonal evolution of myelofibrosis treated with hematopoietic transplantation, using RUXOLITINIB for chronic GvHD: A case report","volume":"66","author":"Fouillet","year":"2018","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1182\/bloodadvances.2018029454","article-title":"Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation","volume":"3","author":"Kong","year":"2019","journal-title":"Blood Adv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.15456","article-title":"Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant","volume":"182","author":"Cao","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/stem.2524","article-title":"Pre-Transplantation Blockade of TNF-\u03b1-Mediated Oxygen Species Accumulation Protects Hematopoietic Stem Cells","volume":"35","author":"Ishida","year":"2017","journal-title":"Stem Cells"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Herrmann, O., Kuepper, M.K., B\u00fctow, M., Costa, I.G., Appelmann, I., Beier, F., Luedde, T., Braunschweig, T., Koschmieder, S., and Br\u00fcmmendorf, T.H. (2019). Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5871-2"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2009-09-241000","article-title":"AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species","volume":"115","author":"Juntilla","year":"2010","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01605","article-title":"Inhibition of Acute Graft-versus-Host Disease with Retention of Graft-versus-Tumor Effects by Dimethyl Fumarate","volume":"8","author":"Han","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2007-07-104042","article-title":"HO-1 underlies resistance of AML cells to TNF-induced apoptosis","volume":"111","author":"Rushworth","year":"2008","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bmt.1704591","article-title":"Rust and corrosion in hematopoietic stem cell transplantation: The problem of iron and oxidative stress","volume":"34","author":"Evens","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.23406","article-title":"Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis","volume":"88","author":"Pardanani","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ejh.12309","article-title":"The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice","volume":"93","author":"Okabe","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e10181","DOI":"10.1038\/srep10181","article-title":"ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem\/progenitor cells in mice","volume":"5","author":"Chai","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2018.11.012","article-title":"Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: Does ferritin decrement matter?","volume":"76","author":"Campagna","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ejh.12674","article-title":"Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase","volume":"96","author":"Latagliata","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"63177","DOI":"10.18632\/oncotarget.18725","article-title":"Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: One facility\u2019s five years\u2019 experience of chelation treatment","volume":"8","author":"Maximova","year":"2017","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:59:27Z","timestamp":1760176767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":145,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082250"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082250","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]}}}